Cobicistat TOS

Phase 3Small molecule

Gilead

Cobicistat TOS is one of 59 small molecule programs targeting Tenofovir. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TenofovirActive, not recruiting

HIV-1 InfectionRecruiting

TenofovirPhase 3

Active, not recruiting

HIV-1 InfectionPhase 3

Recruiting

Competition

Competitive Landscape

66 competitors in HIV-1 Infection

#DrugCompanyPhaseTrials

Tybost

Gilead

Approved

1 2

Epidiolex

Ziagen

Bayer Aspirin

Crestor

Renvela

Oncovin

Istodax

Emtriva

Vemlidy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Active, not recruiting

Tenofovir

NCT02016924

Q1 2034

ApprovedRecruiting

HIV-1 Infection

NCT06337032

Clinical

Trials by Indication[1]

Tenofovir1 trial

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Active, not recruiting· Gilead logo

Gilead·Phase 2/3·NCT02016924·133 enrolled

HIV-1 infection1 trial

An Open-label, Single-arm Study to Provide Continued Access to Study Drug to Participants Who Have Completed Pediatric Clinical Studies Involving Gilead HIV Treatments

Recruiting· Gilead logo

Gilead·Approved·NCT06337032·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cobicistat TOS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cobicistat TOS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cobicistat TOS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Gilead

Cobicistat TOS

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2034

Trials by Indication[1]

Tenofovir1 trial

HIV-1 infection1 trial

References

Drug Info

Quick Facts

Related News